NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|578836290|ref|XP_006723962|]
View 

ICOS ligand isoform X1 [Homo sapiens]

Protein Classification

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

 Name Accession Description Interval E-value
IgV_B7-H2 cd20935
Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of ...
 23-135 4.76e-71

Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of the immunoglobulin variable (IgV) domain of B7-H2 (B7 homolog 2 also known as ICOSL (inducible T cell costimulator ligand) or CD275). B7-H2 is a ligand for the T-cell-specific cell surface receptor ICOS and acts as a costimulatory signal for T-cell proliferation and cytokine secretion. The interaction of ICOS with ICOSL (B7-H2) regulates T cell activation and expansion, is involved in T cell dependent B cell activation, and T-helper cell differentiation. It is a member of the B7 family of immune regulatory proteins and shares homology with other B7 ligands, such as B7-1, B7-2, B7-H1 (PD-L1), PD-L2, and B7-H3. The extracellular domains of B7 proteins contain two Ig-like domains and all members have short cytoplasmic domains. These ligands are typically expressed on antigen presenting cells (such as macrophages, B cells and dendritic cells) and have the ability to regulate T-cell proliferation and function. Tumor cells are also capable of expressing the B7 family members in order to evade immune surveillance.


:

Pssm-ID: 409529  Cd Length: 113  Bit Score: 222.05  E-value: 4.76e-71
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  23 KEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFN 102
Cdd:cd20935    1 KEVRAMVGSDVELSCICPEGSRFDLNDLYVYWQISESETVVTYHLPQNSSLENVDSHYRNRALLSLDSMKQGDFSLRLFN 80

                         90       100       110
                 ....*....|....*....|....*....|...
gi 578836290 103 VTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVA 135
Cdd:cd20935   81 VTPQDEQKFHCLVFSQSLELQKVLEVVVTLHVA 113
PHA03201 super family cl30881
uracil DNA glycosylase; Provisional
 391-470 6.40e-05

uracil DNA glycosylase; Provisional


The actual alignment was detected with superfamily member PHA03201:

Pssm-ID: 165468  Cd Length: 318  Bit Score: 44.88  E-value: 6.40e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 391 PRSPVPSPdqgvqggsrhRRPAPMGCPEWVQAPAPSPRGVSRAGPGTGAQPPWGVQGGSRHRRPAPMGCPEWVQAPAPSP 470
Cdd:PHA03201   4 ARSRSPSP----------PRRPSPPRPTPPRSPDASPEETPPSPPGPGAEPPPGRAAGPAAPRRRPRGCPAGVTFSSSAP 73
Ig super family cl11960
Immunoglobulin domain; The members here are composed of the immunoglobulin (Ig) domain found ...
 149-224 2.28e-04

Immunoglobulin domain; The members here are composed of the immunoglobulin (Ig) domain found in the Ig superfamily. The Ig superfamily is a heterogenous group of proteins, built on a common fold comprised of a sandwich of two beta sheets. Members of this group are components of immunoglobulin, neuroglia, cell surface glycoproteins, including T-cell receptors, CD2, CD4, CD8, and membrane glycoproteins, including butyrophilin and chondroitin sulfate proteoglycan core protein. A predominant feature of most Ig domains is a disulfide bridge connecting the two beta-sheets with a tryptophan residue packed against the disulfide bond. Ig superfamily (IgSF) domains can be divided into 4 main classes based on their structures and sequences: the Variable (V), Constant 1 (C1), Constant 2 (C2), and Intermediate (I) sets. Typically, the V-set domains have A, B, E, and D strands in one sheet and A', G, F, C, C' and C" in the other. The structures in C1-set are smaller than those in the V-set; they have one beta sheet that is formed by strands A, B, E, and D and the other by strands G, F, C, and C'. Moreover, a C1-set Ig domain contains a short C' strand (three residues) and lacks A' and C" strand. Unlike other Ig domain sets, C2-set structures do not have a D strand. Like the V-set Ig domains, members of the I-set have a discontinuous A strand, but lack a C" strand.


The actual alignment was detected with superfamily member cd20986:

Pssm-ID: 472250  Cd Length: 82  Bit Score: 40.02  E-value: 2.28e-04
                         10        20        30        40        50        60        70
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 578836290 149 PSQDELTFTCTSiNGYPRPNVYWINKTdnslldqALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQ 224
Cdd:cd20986    8 PGTGEVQLTCQA-RGYPLAEVSWQNVS-------VPANTSHTRTPEGLYQVTSVLRLKPQPGRNFSCMFWNAHMKE 75
 
Name Accession Description Interval E-value
IgV_B7-H2 cd20935
Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of ...
 23-135 4.76e-71

Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of the immunoglobulin variable (IgV) domain of B7-H2 (B7 homolog 2 also known as ICOSL (inducible T cell costimulator ligand) or CD275). B7-H2 is a ligand for the T-cell-specific cell surface receptor ICOS and acts as a costimulatory signal for T-cell proliferation and cytokine secretion. The interaction of ICOS with ICOSL (B7-H2) regulates T cell activation and expansion, is involved in T cell dependent B cell activation, and T-helper cell differentiation. It is a member of the B7 family of immune regulatory proteins and shares homology with other B7 ligands, such as B7-1, B7-2, B7-H1 (PD-L1), PD-L2, and B7-H3. The extracellular domains of B7 proteins contain two Ig-like domains and all members have short cytoplasmic domains. These ligands are typically expressed on antigen presenting cells (such as macrophages, B cells and dendritic cells) and have the ability to regulate T-cell proliferation and function. Tumor cells are also capable of expressing the B7 family members in order to evade immune surveillance.


Pssm-ID: 409529  Cd Length: 113  Bit Score: 222.05  E-value: 4.76e-71
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  23 KEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFN 102
Cdd:cd20935    1 KEVRAMVGSDVELSCICPEGSRFDLNDLYVYWQISESETVVTYHLPQNSSLENVDSHYRNRALLSLDSMKQGDFSLRLFN 80

                         90       100       110
                 ....*....|....*....|....*....|...
gi 578836290 103 VTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVA 135
Cdd:cd20935   81 VTPQDEQKFHCLVFSQSLELQKVLEVVVTLHVA 113
V-set pfam07686
Immunoglobulin V-set domain; This domain is found in antibodies as well as neural protein P0 ...
 20-131 3.82e-07

Immunoglobulin V-set domain; This domain is found in antibodies as well as neural protein P0 and CTL4 amongst others.


Pssm-ID: 462230  Cd Length: 109  Bit Score: 48.61  E-value: 3.82e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290   20 TQEKEVRAMVGSDVELSCACPegSRFDLNDVYVYW---QTSESKTVVTYHIPQNSSLENVDSRYRNRALMSpagmlRGDF 96
Cdd:pfam07686   1 QTPREVTVALGGSVTLPCTYS--SSMSEASTSVYWyrqPPGKGPTFLIAYYSNGSEEGVKKGRFSGRGDPS-----NGDG 73

                          90       100       110
                  ....*....|....*....|....*....|....*.
gi 578836290   97 SLRLFNVTPQDEQKFHCLVLSQS-LGFQEVLSVEVT 131
Cdd:pfam07686  74 SLTIQNLTLSDSGTYTCAVIPSGeGVFGKGTRLTVL 109
PHA03201 PHA03201
uracil DNA glycosylase; Provisional
 391-470 6.40e-05

uracil DNA glycosylase; Provisional


Pssm-ID: 165468  Cd Length: 318  Bit Score: 44.88  E-value: 6.40e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 391 PRSPVPSPdqgvqggsrhRRPAPMGCPEWVQAPAPSPRGVSRAGPGTGAQPPWGVQGGSRHRRPAPMGCPEWVQAPAPSP 470
Cdd:PHA03201   4 ARSRSPSP----------PRRPSPPRPTPPRSPDASPEETPPSPPGPGAEPPPGRAAGPAAPRRRPRGCPAGVTFSSSAP 73
IGv smart00406
Immunoglobulin V-Type;
32-115 1.38e-04

Immunoglobulin V-Type;


Pssm-ID: 214650  Cd Length: 81  Bit Score: 40.44  E-value: 1.38e-04
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290    32 DVELSCacpEGSRFDLNDVYVYWQT-SESKTVVTYHIPQNSSLENVDSRYRNRALMSpAGMLRGDFSLRLFNVTPQDEQK 110
Cdd:smart00406   1 SVTLSC---KFSGSTFSSYYVSWVRqPPGKGLEWLGYIGSNGSSYYQESYKGRFTIS-KDTSKNDVSLTISNLRVEDTGT 76


                   ....*
gi 578836290   111 FHCLV 115
Cdd:smart00406  77 YYCAV 81
IgC1_PD-L2 cd20986
Immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2); The members here ...
 149-224 2.28e-04

Immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2); The members here are composed of the immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2; also known as B7-DC or CD273). PD-L2 is a cell-surface ligand that competes with PD-L1 for binding to the immunosuppressive receptor programmed death-1 (PD-1). PD-1 is a member of the CD28/B7 family that plays an important role in negatively regulating immune responses upon interaction with its two ligands, PD-L1 or PD-L2. PD-L2 has a higher affinity for PD-1 but is expressed at lower levels. PD-L2 interaction with PD-1 suppresses T cell proliferation, cytokine production and cytotoxic activity. PD-L2 is expressed on tumor cells, antigen-presenting cells or APCs (such as macrophages, B cells and dendritic cells), and a variety of other immune and nonimmune cells. Tumor expression of PD-L2 may contribute to tumor evasion of immune destruction by inactivating T cells. Thus, PD-L2 is a negative predictor for prognosis among solid cancer patients.


Pssm-ID: 409578  Cd Length: 82  Bit Score: 40.02  E-value: 2.28e-04
                         10        20        30        40        50        60        70
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 578836290 149 PSQDELTFTCTSiNGYPRPNVYWINKTdnslldqALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQ 224
Cdd:cd20986    8 PGTGEVQLTCQA-RGYPLAEVSWQNVS-------VPANTSHTRTPEGLYQVTSVLRLKPQPGRNFSCMFWNAHMKE 75
 
Name Accession Description Interval E-value
IgV_B7-H2 cd20935
Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of ...
 23-135 4.76e-71

Immunoglobulin Variable (IgV) domain of B7-H2 (B7 homolog 2); The members here are composed of the immunoglobulin variable (IgV) domain of B7-H2 (B7 homolog 2 also known as ICOSL (inducible T cell costimulator ligand) or CD275). B7-H2 is a ligand for the T-cell-specific cell surface receptor ICOS and acts as a costimulatory signal for T-cell proliferation and cytokine secretion. The interaction of ICOS with ICOSL (B7-H2) regulates T cell activation and expansion, is involved in T cell dependent B cell activation, and T-helper cell differentiation. It is a member of the B7 family of immune regulatory proteins and shares homology with other B7 ligands, such as B7-1, B7-2, B7-H1 (PD-L1), PD-L2, and B7-H3. The extracellular domains of B7 proteins contain two Ig-like domains and all members have short cytoplasmic domains. These ligands are typically expressed on antigen presenting cells (such as macrophages, B cells and dendritic cells) and have the ability to regulate T-cell proliferation and function. Tumor cells are also capable of expressing the B7 family members in order to evade immune surveillance.


Pssm-ID: 409529  Cd Length: 113  Bit Score: 222.05  E-value: 4.76e-71
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  23 KEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFN 102
Cdd:cd20935    1 KEVRAMVGSDVELSCICPEGSRFDLNDLYVYWQISESETVVTYHLPQNSSLENVDSHYRNRALLSLDSMKQGDFSLRLFN 80

                         90       100       110
                 ....*....|....*....|....*....|...
gi 578836290 103 VTPQDEQKFHCLVLSQSLGFQEVLSVEVTLHVA 135
Cdd:cd20935   81 VTPQDEQKFHCLVFSQSLELQKVLEVVVTLHVA 113
IgV_B7-H3 cd20934
Immunoglobulin Variable (IgV) domain of B7-H3, a member of the B7 family of immune checkpoint ...
 22-138 1.33e-12

Immunoglobulin Variable (IgV) domain of B7-H3, a member of the B7 family of immune checkpoint molecules; The members here are composed of the immunoglobulin variable (IgV) domain of B7-H3 also known as CD276), a member of the B7 family of immune checkpoint molecules. B7-H3 is an important immune checkpoint member of the B7 family and shares homology with other B7 ligands such as programmed death ligand 1 (PD-L1). The B7 family molecules interact with CD28 on T-cells to provide co-stimulatory signals that regulate T-cell activation and T-helper cell differentiation. Although B7-H3 has been shown to have both co-stimulatory and co-inhibitory effects on T-cell responses, the most current studies describe B7-H3 as a T cell inhibitor that promotes tumor aggressiveness and proliferation. Moreover, B7-H3 is highly overexpressed on a wide range of human solid cancers and promotes tumor growth, metastasis, and drug resistance. Thus, B7-H3 expression in tumors often correlates with both negative prognosis and poor clinical outcome in cancer patients. B7-H3 protein contains a predicted signal peptide, V- and C-like Ig domains (IgV and IgC), a transmembrane region, and an intracellular tail.


Pssm-ID: 409528  Cd Length: 115  Bit Score: 64.55  E-value: 1.33e-12
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  22 EKEVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLF 101
Cdd:cd20934    4 EDPVVALVGTDATLRCSFSPEPGFSLAQLSVFWQLTDTKQLVHSFTESQDQGRDQGSAYANRTALFPDLLAQGNASLRLQ 83

                         90       100       110
                 ....*....|....*....|....*....|....*..
gi 578836290 102 NVTPQDEQKFHCLVLSQSLGfqevlSVEVTLHVAANF 138
Cdd:cd20934   84 RVRVADEGSYTCFVSVQDFG-----SAAVSLQVAAPF 115
IgV_HHLA2 cd16091
Immunoglobulin Variable (IgV) domain in HERV-H LTR-associating 2 (HHLA2); The members here are ...
 19-115 4.55e-08

Immunoglobulin Variable (IgV) domain in HERV-H LTR-associating 2 (HHLA2); The members here are composed of the immunoglobulin variable (IgV) region in HERV-H LTR-associating 2 (HHLA2; also known as B7-H7/B7 homolog 7). HHLA2 is a member of the B7 family of immune regulatory proteins. Mature human HHLA2 consists of an extracellular domain (ECD) with three immunoglobulin-like domains, a transmembrane segment, and a cytoplasmic domain. HHLA2 is widely expressed in human cancers including non-small cell lung carcinoma (NSCLS), triple negative breast cancer (TNBC), and melanoma, but has limited expression on normal tissues. Interestingly, unlike other members of B7 family, HHLA2 is not expressed in mice or rats. HHLA2 functions as a T cell coinhibitory molecules as it inhibits the proliferation of activated CD4(+) and CD8(+) T cells and their cytokine production. Furthermore, HHLA2 is constitutively expressed on the surface of human monocytes and is induced on B cells after stimulation, however it is not inducible on T cells.


Pssm-ID: 409512  Cd Length: 107  Bit Score: 51.23  E-value: 4.55e-08
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  19 DTQEKEVRAMVGSDVELSCACPEGSrfdlnDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSL 98
Cdd:cd16091    1 AVSEVIVVCLLSEDCILPCSFTPGS-----EVVIHWYKQDSDIKVHSYYYGKDQLESQDQRYRNRTSLFKDQISNGNASL 75

                         90
                 ....*....|....*..
gi 578836290  99 RLFNVTPQDEQKFHCLV 115
Cdd:cd16091   76 LLRRVQLQDEGRYKCYT 92
V-set pfam07686
Immunoglobulin V-set domain; This domain is found in antibodies as well as neural protein P0 ...
 20-131 3.82e-07

Immunoglobulin V-set domain; This domain is found in antibodies as well as neural protein P0 and CTL4 amongst others.


Pssm-ID: 462230  Cd Length: 109  Bit Score: 48.61  E-value: 3.82e-07
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290   20 TQEKEVRAMVGSDVELSCACPegSRFDLNDVYVYW---QTSESKTVVTYHIPQNSSLENVDSRYRNRALMSpagmlRGDF 96
Cdd:pfam07686   1 QTPREVTVALGGSVTLPCTYS--SSMSEASTSVYWyrqPPGKGPTFLIAYYSNGSEEGVKKGRFSGRGDPS-----NGDG 73

                          90       100       110
                  ....*....|....*....|....*....|....*.
gi 578836290   97 SLRLFNVTPQDEQKFHCLVLSQS-LGFQEVLSVEVT 131
Cdd:pfam07686  74 SLTIQNLTLSDSGTYTCAVIPSGeGVFGKGTRLTVL 109
IgV_MOG_like cd05713
Immunoglobulin (Ig)-like domain of myelin oligodendrocyte glycoprotein (MOG); The members here ...
 25-135 6.60e-06

Immunoglobulin (Ig)-like domain of myelin oligodendrocyte glycoprotein (MOG); The members here are composed of the immunoglobulin (Ig)-like domain of myelin oligodendrocyte glycoprotein (MOG). MOG, a minor component of the myelin sheath, is an important CNS-specific autoantigen, linked to the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). It is a transmembrane protein having an extracellular Ig domain. MOG is expressed in the CNS on the outermost lamellae of the myelin sheath, and on the surface of oligodendrocytes, and may participate in the completion, compaction, and/or maintenance of myelin. This group also includes butyrophilin (BTN). BTN is the most abundant protein in bovine milk-fat globule membrane (MFGM).


Pssm-ID: 409378  Cd Length: 114  Bit Score: 45.26  E-value: 6.60e-06
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  25 VRAMVGSDVELSCAC-PEGSrfdLNDVYVYWQTSESKTVVtyHIPQNSslENVDSR----YRNRALMSPAGMLRGDFSLR 99
Cdd:cd05713   10 ILALVGEDAELPCHLsPKMS---AEHMEVRWFRSQFSPVV--HLYRDG--QDQEEEqmpeYRGRTELLKDAIAEGSVALR 82

                         90       100       110
                 ....*....|....*....|....*....|....*.
gi 578836290 100 LFNVTPQDEQKFHCLVlsQSLGFQEVLSVEvtLHVA 135
Cdd:cd05713   83 IHNVRPSDEGQYTCFF--RSGSFYEEATLE--LKVA 114
IgV_PDl1 cd20947
Immunoglobulin Variable (IgV) domain of Programmed death ligand 1 (PD-L1); The members here ...
 30-115 3.44e-05

Immunoglobulin Variable (IgV) domain of Programmed death ligand 1 (PD-L1); The members here are composed of the immunoglobulin variable (IgV) domain of Programmed death ligand 1 (PD-L1; also known as Cluster of Differentiation 274 (CD274)). PD-L1 is a cell-surface ligand that competes with PD-L2 for binding to the immunosuppressive receptor programmed death-1 (PD-1). PD-1 is a member of the B7 family that plays an important role in negatively regulating immune responses upon interaction with its two ligands, PD-L1 or PD-L2. Like PD-L2, PD-L1 interacts with PD-1 and suppresses T cell proliferation and cytokine production. The PD-1 receptor is expressed on the surface of activated T cells, while PD-L1 is expressed on cancer cells. When PD-1 and PD-L1 bind together, they form a molecular shield protecting tumor cells from being destroyed by the immune system. Thus, inhibiting the binding of PD-L1 to PD-1 with an antibody leads to killing of tumor cells by T cells. PD-1 inhibitors (such as Pembrolizumab, Nivolumab, and Cemiplimab) and PD-L1 inhibitors (such as Atezolizumab, Avelumab, and Durvalumab ) are an emerging class of immunotherapy that stimulate lymphocytes against tumor cells.


Pssm-ID: 409539  Cd Length: 110  Bit Score: 43.00  E-value: 3.44e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  30 GSDVELSCACPEGSRFDLNDVYVYWQTSESKTVVTYHIPQNSSLENvdSRYRNRALMSPAGMLRGDFSLRLFNVTPQDEQ 109
Cdd:cd20947   13 GSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQH--SSYRQRARLLKDQLSLGNAALQITDVKLQDAG 90


                 ....*.
gi 578836290 110 KFHCLV 115
Cdd:cd20947   91 VYRCMI 96
IgV_B7-H4 cd20984
Immunoglobulin Variable (IgV) domain of B7-H4; The members here are composed of the ...
 27-117 4.64e-05

Immunoglobulin Variable (IgV) domain of B7-H4; The members here are composed of the immunoglobulin variable (IgV) domain of B7-H4 (also known as B7-S1, B7x, or Vtcn1). B7-H4 is one of the B7 family of immune-regulatory ligands that act as negative regulators of T cell function; it contains one IgV domain and one IgC domain. The B7-family consists of structurally related cell-surface protein ligands, which bind to receptors on lymphocytes that regulate immune responses. The binding of B7-H4 to unidentified receptors results in the inhibition of TCR-mediated T cell proliferation, cell-cycle progression and IL-2 production. As a co-inhibitory molecule, B7-H4 is widely expressed in tumor tissues and its expression is significantly associated with poor prognosis in human cancers such as glioma, pancreatic cancer, oral squamous cell carcinoma, renal cell carcinoma, and lung cancer.


Pssm-ID: 409576  Cd Length: 110  Bit Score: 42.59  E-value: 4.64e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  27 AMVGSDVELSCA-CPEgsrFDLNDVYVYWQTSESKTVVTYHIPQNSSLENVDSRYRNRALMSPAGMLRGDFSLRLFNVTP 105
Cdd:cd20984    9 GNIGEDGILSCTfTPD---IKLSDIVIQWLKEGDSGLVHEFKEGKDELSRQSPMFRGRTSLFADQVHVGNASLRLKNVQL 85

                         90
                 ....*....|..
gi 578836290 106 QDEQKFHCLVLS 117
Cdd:cd20984   86 TDAGTYLCIISN 97
PHA03201 PHA03201
uracil DNA glycosylase; Provisional
 391-470 6.40e-05

uracil DNA glycosylase; Provisional


Pssm-ID: 165468  Cd Length: 318  Bit Score: 44.88  E-value: 6.40e-05
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 391 PRSPVPSPdqgvqggsrhRRPAPMGCPEWVQAPAPSPRGVSRAGPGTGAQPPWGVQGGSRHRRPAPMGCPEWVQAPAPSP 470
Cdd:PHA03201   4 ARSRSPSP----------PRRPSPPRPTPPRSPDASPEETPPSPPGPGAEPPPGRAAGPAAPRRRPRGCPAGVTFSSSAP 73
IGv smart00406
Immunoglobulin V-Type;
32-115 1.38e-04

Immunoglobulin V-Type;


Pssm-ID: 214650  Cd Length: 81  Bit Score: 40.44  E-value: 1.38e-04
                           10        20        30        40        50        60        70        80
                   ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290    32 DVELSCacpEGSRFDLNDVYVYWQT-SESKTVVTYHIPQNSSLENVDSRYRNRALMSpAGMLRGDFSLRLFNVTPQDEQK 110
Cdd:smart00406   1 SVTLSC---KFSGSTFSSYYVSWVRqPPGKGLEWLGYIGSNGSSYYQESYKGRFTIS-KDTSKNDVSLTISNLRVEDTGT 76


                   ....*
gi 578836290   111 FHCLV 115
Cdd:smart00406  77 YYCAV 81
PRK07764 PRK07764
DNA polymerase III subunits gamma and tau; Validated
 395-515 2.10e-04

DNA polymerase III subunits gamma and tau; Validated


Pssm-ID: 236090 [Multi-domain]  Cd Length: 824  Bit Score: 44.21  E-value: 2.10e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 395 VPSPDQGVQGGSRHRRPAPMGCPEWVQAPAPSPRGVSRAGPGTGAQPPwgvqggsrHRRPAPMGCPEWVQAPAPSPRGVC 474
Cdd:PRK07764 587 VVGPAPGAAGGEGPPAPASSGPPEEAARPAAPAAPAAPAAPAPAGAAA--------APAEASAAPAPGVAAPEHHPKHVA 658

                         90       100       110       120
                 ....*....|....*....|....*....|....*....|.
gi 578836290 475 RAGPGTGAQPlWGVRSGSGHRQLLSVAATPAALVCPSVPGA 515
Cdd:PRK07764 659 VPDASDGGDG-WPAKAGGAAPAAPPPAPAPAAPAAPAGAAP 698
IgV_CD86 cd16087
Immunoglobulin variable domain (IgV) in Cluster of Differentiation (CD) 86; The members here ...
 24-115 2.13e-04

Immunoglobulin variable domain (IgV) in Cluster of Differentiation (CD) 86; The members here are composed of the immunoglobulin variable region (IgV) in the Cluster of Differentiation (CD) 86). Glycoproteins B7-1 (also known as cluster of differentiation (CD) 80) and B7-2 (also known as CD86) are expressed on antigen-presenting cells and deliver the co-stimulatory signal through CD28 and CTLA-4 (also known as CD152) on T cells. signaling through CD28 augments the T-cell response, whereas CTLA-4 signaling attenuates it. The CTLA-4 and B7-2 monomers are both two-layer beta-sandwiches that display the chain topology characteristic of the immunoglobulin variable (V-type) domains present in antigen receptors. The front and back sheets of B7-2 are composed of AGFCC'C" and BED strands, respectively. Members of the IgV family are components of immunoglobulin (Ig) and T cell receptors. The basic structure of Ig molecules is a tetramer of two light chains and two heavy chains linked by disulfide bonds. In Ig, each chain is composed of one variable domain (IgV) and one or more constant domains (IgC); these names reflect the fact that the variability in sequences is higher in the variable domain than in the constant domain. Within the variable domain, there are regions of even more variability called the hypervariable or complementarity-determining regions (CDRs) which are responsible for antigen binding. A predominant feature of most Ig domains is the disulfide bridge connecting 2 beta-sheets with a tryptophan residue packed against the disulfide bond.


Pssm-ID: 409508  Cd Length: 108  Bit Score: 40.77  E-value: 2.13e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  24 EVRAMVGSDVELSCACPEGSRFDLNDVYVYWQTSESKtvVTYHIPQNSS-LENVDSRYRNRALMSpagmlRGDFSLRLFN 102
Cdd:cd16087    2 KIQAYFNETAYLPCQFKNPQNISLSELVVFWQDQKKL--VLYELYLGKEkLDNVNSKYIGRTSFD-----QENWTLQLHN 74

                         90
                 ....*....|...
gi 578836290 103 VTPQDEQKFHCLV 115
Cdd:cd16087   75 VQIKDQGTYQCFI 87
IgC1_PD-L2 cd20986
Immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2); The members here ...
 149-224 2.28e-04

Immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2); The members here are composed of the immunoglobulin Constant 1 (IgC1) domain of Programmed death ligand 2 (PD-L2; also known as B7-DC or CD273). PD-L2 is a cell-surface ligand that competes with PD-L1 for binding to the immunosuppressive receptor programmed death-1 (PD-1). PD-1 is a member of the CD28/B7 family that plays an important role in negatively regulating immune responses upon interaction with its two ligands, PD-L1 or PD-L2. PD-L2 has a higher affinity for PD-1 but is expressed at lower levels. PD-L2 interaction with PD-1 suppresses T cell proliferation, cytokine production and cytotoxic activity. PD-L2 is expressed on tumor cells, antigen-presenting cells or APCs (such as macrophages, B cells and dendritic cells), and a variety of other immune and nonimmune cells. Tumor expression of PD-L2 may contribute to tumor evasion of immune destruction by inactivating T cells. Thus, PD-L2 is a negative predictor for prognosis among solid cancer patients.


Pssm-ID: 409578  Cd Length: 82  Bit Score: 40.02  E-value: 2.28e-04
                         10        20        30        40        50        60        70
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 578836290 149 PSQDELTFTCTSiNGYPRPNVYWINKTdnslldqALQNDTVFLNMRGLYDVVSVLRIARTPSVNIGCCIENVLLQQ 224
Cdd:cd20986    8 PGTGEVQLTCQA-RGYPLAEVSWQNVS-------VPANTSHTRTPEGLYQVTSVLRLKPQPGRNFSCMFWNAHMKE 75
PRK12323 PRK12323
DNA polymerase III subunit gamma/tau;
387-515 2.56e-04

DNA polymerase III subunit gamma/tau;


Pssm-ID: 237057 [Multi-domain]  Cd Length: 700  Bit Score: 43.71  E-value: 2.56e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 387 SARLPRSPVPSPDQGVQGGSRHRR---PAPMGCPEWVQAPAPSPRGVSRAGPGTGAQPPWGVQGGSRHRRPAPMGCPEW- 462
Cdd:PRK12323 421 AAPARRSPAPEALAAARQASARGPggaPAPAPAPAAAPAAAARPAAAGPRPVAAAAAAAPARAAPAAAPAPADDDPPPWe 500

                         90       100       110       120       130
                 ....*....|....*....|....*....|....*....|....*....|....*...
gi 578836290 463 -----VQAPAPSPRGVCRAGPGTGAQPLWGVRSGSGHRQLLSVAATPAALVCPSVPGA 515
Cdd:PRK12323 501 elppeFASPAPAQPDAAPAGWVAESIPDPATADPDDAFETLAPAPAAAPAPRAAAATE 558
IgV_1_JAM1-like cd20946
First Ig-like domain of Junctional adhesion molecule-1 (JAM1)and similar domains; a member of ...
 18-134 3.09e-04

First Ig-like domain of Junctional adhesion molecule-1 (JAM1)and similar domains; a member of the V-set of IgSF domains; The members here are composed of the first Ig-like domain of Junctional Adhesion Molecule-1 (JAM1)and similar domains. JAM1 is an immunoglobulin superfamily (IgSF) protein with two Ig-like domains in its extracellular region; it plays a role in the formation of endothelial and epithelial tight junction and acts as a receptor for mammalian reovirus sigma-1. The IgSF is a heterogenous group of proteins, built on a common fold comprised of a sandwich of two beta sheets. The two sheets are linked together by a conserved disulfide bond between B strand and F strand. IgSF domains can be divided into 4 main classes based on their structures and sequences: the Variable (V), Constant 1 (C1), Constant 2 (C2), and Intermediate (I) sets. The first Ig-like domain of JAM1 is a member of the V-set Ig domains, having A-B-E-D strands in one beta-sheet and A'-G-F-C-C'-C" in the other.


Pssm-ID: 409538  Cd Length: 102  Bit Score: 40.21  E-value: 3.09e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290  18 ADTQEKEVRAMVGSDVELSCACPEGSrfdlNDVYVYWQTSESKtvVTYHIPQNSSLEnvdSRYRNRALMSPagmlrgdFS 97
Cdd:cd20946    2 VPSSQQVVTVVENQEVILSCKTPKKT----SSPRVEWKKLQRD--VTFVVFQNNKIQ---GDYKGRAEILG-------TN 65

                         90       100       110
                 ....*....|....*....|....*....|....*..
gi 578836290  98 LRLFNVTPQDEQKFHCLVLSQSlGFQEVLSVEVTLHV 134
Cdd:cd20946   66 ITIKNVTRSDSGKYRCEVSARS-DGQNLGEVTVTLEV 101
PHA03378 PHA03378
EBNA-3B; Provisional
 386-484 8.67e-04

EBNA-3B; Provisional


Pssm-ID: 223065 [Multi-domain]  Cd Length: 991  Bit Score: 41.98  E-value: 8.67e-04
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 386 TSARLPRSPvPSPDQGVQGGSRHRRPaPMGCPEWVQAPAPSP-RGVSRAGPGTGAQPPWGVQGGSRHR-----RPAPMGC 459
Cdd:PHA03378 702 TPMRPPAAP-PGRAQRPAAATGRARP-PAAAPGRARPPAAAPgRARPPAAAPGRARPPAAAPGRARPPaaapgAPTPQPP 779

                         90       100
                 ....*....|....*....|....*
gi 578836290 460 PewvQAPaPSPRGVCRAGPGTGAQP 484
Cdd:PHA03378 780 P---QAP-PAPQQRPRGAPTPQPPP 800
PRK07764 PRK07764
DNA polymerase III subunits gamma and tau; Validated
 393-490 2.33e-03

DNA polymerase III subunits gamma and tau; Validated


Pssm-ID: 236090 [Multi-domain]  Cd Length: 824  Bit Score: 40.74  E-value: 2.33e-03
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 393 SPVPSPDQGVQGGSRHRRPAPMGCPEWVQAPAPSP------RGVSRAGPGTGAQPPWGVQGGSRHRRPAPMGCPEWVQAP 466
Cdd:PRK07764 411 APAAAAPAAAAAPAPAAAPQPAPAPAPAPAPPSPAgnapagGAPSPPPAAAPSAQPAPAPAAAPEPTAAPAPAPPAAPAP 490

                         90       100
                 ....*....|....*....|....
gi 578836290 467 APSPRGVCRAGPGTGAQPLWGVRS 490
Cdd:PRK07764 491 AAAPAAPAAPAAPAGADDAATLRE 514
PRK07764 PRK07764
DNA polymerase III subunits gamma and tau; Validated
 391-506 3.58e-03

DNA polymerase III subunits gamma and tau; Validated


Pssm-ID: 236090 [Multi-domain]  Cd Length: 824  Bit Score: 39.97  E-value: 3.58e-03
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 578836290 391 PRSPVPSPDQGVQGGSRHRRPAPMGCPEWVQAPAPSPRGVSRAGPGTGAQpPWGVQGGSrhrrPAPMGcPEWVQAPAPSP 470
Cdd:PRK07764 618 PAAPAAPAAPAPAGAAAAPAEASAAPAPGVAAPEHHPKHVAVPDASDGGD-GWPAKAGG----AAPAA-PPPAPAPAAPA 691

                         90       100       110
                 ....*....|....*....|....*....|....*.
gi 578836290 471 RGVCRAGPGTGAQPLWGVRSGSGHRQLLSVAATPAA 506
Cdd:PRK07764 692 APAGAAPAQPAPAPAATPPAGQADDPAAQPPQAAQG 727
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH